Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

728 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Photodynamic diagnosis-assisted transurethral resection of bladder tumor for high-risk non-muscle invasive bladder cancer improves intravesical recurrence-free survival (BRIGHT study).
Kawai T, Matsuyama H, Kobayashi K, Ikeda A, Miyake M, Nishimoto K, Matsushita Y, Nishiyama H, Fujimoto K, Oyama M, Miyake H, Azuma H, Inoue K, Mitsui T, Kawakita M, Oyama C, Mizokami A, Abe T, Kuroiwa H, Kume H. Kawai T, et al. Among authors: oyama m. Int J Urol. 2024 May 2. doi: 10.1111/iju.15483. Online ahead of print. Int J Urol. 2024. PMID: 38695571
Differences in oncological benefits from second transurethral resection between white-light initial surgery and photodynamic diagnosis-guided initial surgery for primary high-risk non-muscle invasive bladder cancer.
Miyake M, Nishimura N, Nakahama T, Nishimoto K, Oyama M, Matsushita Y, Miyake H, Fukuhara H, Inoue K, Kobayashi K, Matsuyama H, Fujii T, Hirao Y, Fujimoto K. Miyake M, et al. Among authors: oyama m. Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15474. Online ahead of print. Int J Urol. 2024. PMID: 38687165
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.
Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators. Choueiri TK, et al. N Engl J Med. 2024 Apr 18;390(15):1359-1371. doi: 10.1056/NEJMoa2312695. N Engl J Med. 2024. PMID: 38631003 Clinical Trial.
Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.
Tokuyasu D, Suzuki S, Uzawa A, Nagane Y, Masuda M, Konno S, Kubota T, Samukawa M, Sugimoto T, Ishizuchi K, Oyama M, Yasuda M, Akamine H, Onishi Y, Suzuki Y, Kawaguchi N, Minami N, Kimura T, Takahashi MP, Murai H, Utsugisawa K. Tokuyasu D, et al. Among authors: oyama m. Ann Clin Transl Neurol. 2024 Apr 4. doi: 10.1002/acn3.52051. Online ahead of print. Ann Clin Transl Neurol. 2024. PMID: 38572524 Free article.
MucoRice-CTB line 19A, a new marker-free transgenic rice-based cholera vaccine produced in an LED-based hydroponic system.
Yuki Y, Kurokawa S, Sugiura K, Kashima K, Maruyama S, Yamanoue T, Honma A, Mejima M, Takeyama N, Kuroda M, Kozuka-Hata H, Oyama M, Masumura T, Nakahashi-Ouchida R, Fujihashi K, Hiraizumi T, Goto E, Kiyono H. Yuki Y, et al. Among authors: oyama m. Front Plant Sci. 2024 Mar 15;15:1342662. doi: 10.3389/fpls.2024.1342662. eCollection 2024. Front Plant Sci. 2024. PMID: 38559768 Free PMC article.
Pathologic Features of Anti-Ku Myositis.
Oyama M, Holzer MT, Ohnuki Y, Saito Y, Nishimori Y, Suzuki S, Shiina T, Leonard-Louis S, Benveniste O, Schneider U, Stenzel W, Nishino I, Suzuki S, Uruha A. Oyama M, et al. Neurology. 2024 Apr 23;102(8):e209268. doi: 10.1212/WNL.0000000000209268. Epub 2024 Mar 28. Neurology. 2024. PMID: 38547417
728 results